Gan & Lee Pharmaceuticals
SSE:603087

Watchlist Manager
Gan & Lee Pharmaceuticals Logo
Gan & Lee Pharmaceuticals
SSE:603087
Watchlist
Price: 44.81 CNY -4.7% Market Closed
Market Cap: 26.5B CNY
Have any thoughts about
Gan & Lee Pharmaceuticals?
Write Note

Relative Value

The Relative Value of one Gan & Lee Pharmaceuticals stock under the Base Case scenario is 66.33 CNY. Compared to the current market price of 44.81 CNY, Gan & Lee Pharmaceuticals is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
66.33 CNY
Undervaluation 32%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
50
vs Industry
46
Median 3Y
10.4
Median 5Y
10.9
Industry
7.7
Forward
8.1
vs History
36
vs Industry
3
Median 3Y
29.9
Median 5Y
46.2
Industry
22.7
Forward
40.3
vs History
18
vs Industry
1
Median 3Y
38.5
Median 5Y
42.9
Industry
21.6
vs History
vs Industry
Median 3Y
-30.1
Median 5Y
-22.6
Industry
25.2
vs History
52
vs Industry
37
Median 3Y
2.4
Median 5Y
2.7
Industry
2.5
vs History
43
vs Industry
40
Median 3Y
9.4
Median 5Y
9.8
Industry
7.7
Forward
7.5
vs History
38
vs Industry
32
Median 3Y
12.3
Median 5Y
12.7
Industry
9
vs History
14
vs Industry
1
Median 3Y
25.4
Median 5Y
26.9
Industry
4.2
Forward
26.9
vs History
14
vs Industry
0
Median 3Y
25.4
Median 5Y
26.9
Industry
4.1
Forward
51.7
vs History
16
vs Industry
1
Median 3Y
34.4
Median 5Y
38.6
Industry
5.7
vs History
vs Industry
Median 3Y
-26.9
Median 5Y
-17.8
Industry
3.6
vs History
61
vs Industry
42
Median 3Y
2.7
Median 5Y
3.2
Industry
4.6

Multiples Across Competitors

Competitors Multiples
Gan & Lee Pharmaceuticals Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Gan & Lee Pharmaceuticals
SSE:603087
26.9B CNY 10 53.4 116.9 116.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD 10.9 -242.3 24.1 25.3
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 5.9 17.5 15.9 17.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.8B EUR 18.7 -131 -105.5 -76.9
P/E Multiple
Earnings Growth
CN
Gan & Lee Pharmaceuticals
SSE:603087
Average P/E: 182.4
53.4
334%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -242.3
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -131 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
Gan & Lee Pharmaceuticals
SSE:603087
Average EV/EBITDA: 31.4
116.9
839%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.5 N/A
EV/EBIT Multiple
EBIT Growth
CN
Gan & Lee Pharmaceuticals
SSE:603087
Average EV/EBIT: 36
116.9
637%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.9 N/A

See Also

Discover More
Back to Top